➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Harvard Business School
Merck
Medtronic
McKinsey

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,039,780


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,039,780 protect, and when does it expire?

Patent 10,039,780 protects KENGREAL and is included in one NDA.

This patent has twelve patent family members in eleven countries.

Summary for Patent: 10,039,780
Title:Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Inventor(s): Dutta; Panna (Fleminton, NJ), Rafai Far; Adel (Mount-Royal, CA), Ding; Min (Irvington, NY), Motheram; Rajeshwar (Dayton, NJ)
Assignee: Chiesi Farmaceutici S.p.A. (Parma, IT)
Application Number:15/643,745
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,039,780
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 10,039,780

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Chiesi KENGREAL cangrelor POWDER;INTRAVENOUS 204958-001 Jun 22, 2015 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial METHOD OF REDUCING THE RISK OF PERIPROCEDURAL MYOCARDIAL INFARCTION, AND STENT THROMBOSIS IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND THEN A CONTINUOUS INFUSION ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,039,780

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil 112017014996 ⤷  Free Forever Trial
Canada 2971868 ⤷  Free Forever Trial
Chile 2017001840 ⤷  Free Forever Trial
China 107206014 ⤷  Free Forever Trial
Colombia 2017006958 ⤷  Free Forever Trial
European Patent Office 3244900 ⤷  Free Forever Trial
South Korea 20170103848 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
McKesson
Boehringer Ingelheim
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.